Ticker brief
CAPR
last close
·
1 day
·
14 days
·
mkt cap
·
signals 14d
11
authors 14d
8
No price history on file for this name (likely non-equity or unlisted) — the “since then” column below stays blank.
Sentiment — last 14 days
daily mean sentiment, 2026-06-26 → 2026-07-01 · now +0.45 (−1 bearish … +1 bullish)
Who spoke8
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @PersimmonTI | A | -0.32 | 4 | -0.51 |
| @adamfeuerstein | A | +1.05 | 1 | +0.10 |
| @OzmosiHealth | C | · | 1 | +0.25 |
| @tenet_research | C | -2.08 | 1 | +0.25 |
| @Quantumup1 | C | -1.95 | 1 | +0.00 |
| @buzztickr | C | · | 1 | -0.10 |
| @scetrader | C | -1.51 | 1 | +0.00 |
| @PK_Fund | C | +0.19 | 1 | +0.45 |
Recent signals11of 11 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-07-01 | @PK_Fund | +0.45 | Preclinical deramiocel data showed improved diaphragm muscle function in mice. | · | tweet ↗ |
| 2026-06-29 | @PersimmonTI | -0.25 | Sarcastic 'all that winning' on CAPR implies skepticism. | · | tweet ↗ |
| 2026-06-29 | @PersimmonTI | -0.65 | No position, but thinks shares will likely be down significantly on AdCom briefing docs. | · | tweet ↗ |
| 2026-06-29 | @scetrader | +0.00 | Institutional option flow analysis list without standalone direction. | · | tweet ↗ |
| 2026-06-28 | @PersimmonTI | -0.55 | Not positive about deramiocel prospects for Capricor. | · | tweet ↗ |
| 2026-06-28 | @PersimmonTI | -0.60 | Predicts mixed REPL AdCom vote and negative CAPR vote. | · | tweet ↗ |
| 2026-06-26 | @buzztickr | -0.10 | Daily breakout watchlist with spotted/current prices, returns, and mention counts. | · | tweet ↗ |
| 2026-06-26 | @Quantumup1 | +0.00 | TD Cowen initiated DYN at Buy, citing KOL checks and late-stage programs. | · | tweet ↗ |
| 2026-06-26 | @tenet_research | +0.25 | Capricor announces FDA advisory committee meeting to review BLA for Deramiocel. | · | tweet ↗ |
| 2026-06-26 | @OzmosiHealth | +0.25 | Capricor to present positive five-year HOPE-2 OLE data and HOPE-3 Phase 3 results. | · | tweet ↗ |
| 2026-06-26 | @adamfeuerstein | +0.10 | FDA advisory committee reviews scheduled for CAPR and REPL in late July. | · | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.